Skip to main content

IDWeek 2024 Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

Back

Erica Chilson, PharmD

Senior Director, US Medical Affairs
Pfizer

Disclosure(s): Pfizer Inc: Employee, Stocks/Bonds (Public Company)

Poster(s):

(P-8) Assessment of 13-valent pneumococcal conjugate vaccine effectiveness among people living with HIV in the United States

Thursday, October 17, 2024
12:15 PM – 1:30 PM US PT
(P-603) Potential Public Health Impact of Respiratory Syncytial Virus (RSV) Vaccines for Prevention of RSV Among Older Adults in the United States

Thursday, October 17, 2024
12:15 PM – 1:30 PM US PT
(P-604) Preliminary real-world Abrysvo vaccine effectiveness (VE) against Respiratory Syncytial Virus (RSV)-related lower respiratory tract disease (LRTD) hospitalizations and emergency department (ED) visits—Kaiser Permanente of Southern California (KPSC), November 2023-April 2024

Thursday, October 17, 2024
12:15 PM – 1:30 PM US PT
(P-682) The Risk of Cardiorespiratory Events for up to 180 days Following Respiratory Syncytial Virus (RSV) Infection Hospitalization: A Self-controlled Case Series Analysis

Thursday, October 17, 2024
12:15 PM – 1:30 PM US PT